Ferring Pharmaceuticals, Inc.
A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy
- Conditions
- Bowel Preparation
- Interventions
- Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral SolutionDrug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 917
- Registration Number
- NCT03017235
- Locations
- 🇺🇸
Wake Research Associates, LLC, Raleigh, North Carolina, United States
🇺🇸GW Research, Inc., Chula Vista, California, United States
🇺🇸Connecticut Clinical Research Foundation, Bristol, Connecticut, United States
A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur®
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 297
- Registration Number
- NCT02935335
- Locations
- 🇫🇷
Hospital FOCH (there may be other sites in this country), Suresnes, France
A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT02929407
- Locations
- 🇪🇸
Hospital Clinic de Barcelona, Departamento hepatología, Barcelona, Spain
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 190
- Registration Number
- NCT02905682
- Locations
- 🇯🇵
Investigational site (there may be other sites in this country), Tokyo, Japan
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 342
- Registration Number
- NCT02904759
- Locations
- 🇯🇵
Investigational site (there may be other sites in this country), Tokyo, Japan
Safety and Efficacy of Firmagon® (Degarelix) for Injection
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 368
- Registration Number
- NCT02886598
- Locations
- 🇰🇷
Gangnam Severance Hospital (there may be other sites in this country), Seoul, Korea, Republic of
A Study on Efficacy and Safety of Menopur® Multidose in Korean Female Patients With Infertility
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 412
- Registration Number
- NCT02835469
- Locations
- 🇰🇷
CL Hospital (there may be other sites in this country), Gwangju, Korea, Republic of
A Study to Investigate Interleukin-6 (IL-6) and IL-6/Soluble IL-6 Receptor (sIL-6R) Complex Levels in Subjects With Active Inflammatory Bowel Disease
- Conditions
- Inflammatory Bowel Disease
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT02790281
- Locations
- 🇸🇪
Skane University Hospital (there may be other sites in this country), Lund, Sweden
🇩🇰Herlev hospital (there may be other sites in this country), Herlev, Denmark
ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
- Conditions
- Superficial Bladder Cancer
- Interventions
- Biological: ADSTILADRIN
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 157
- Registration Number
- NCT02773849
- Locations
- 🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸Spectrum Health Medical Group, Grand Rapids, Michigan, United States
🇺🇸West Virginia University Cancer Institute, Morgantown, West Virginia, United States
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 230
- Registration Number
- NCT02726009
- Locations
- 🇮🇳
Shalby Hospital, Ahmedabad, India
🇮🇳HealthCare Global Enterprises Limited, Bangalore, India
🇮🇳Bodyline Hospitals, Ahmedabad, India